Advanced Search

Central Nervous System Diseases Stocks List

Symbol Grade Name % Change
BLRX D BioLineRx Ltd. -1.09
SUPN A Supernus Pharmaceuticals, Inc. 1.85
CBMG A Cellular Biomedicine Group, Inc. 0.00
NERV F Minerva Neurosciences, Inc 0.41
AVXL D Anavex Life Sciences Corp. -4.17
CYCN F Cyclerion Therapeutics, Inc. 1.85
View As Page of Charts
Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic
Related Stock Lists: Central Nervous System Disease Treatment Of Central Nervous System Diseases Biopharmaceutical Cancers Clinical Research Clinical Trial Drug Discovery Investigational New Drug Neuroscience Pain Pharmacology Schizophrenia Acute Myeloid Leukemia Alzheimer's Alzheimer's Disease Antidepressants Attention Deficit Attention Deficit Hyperactivity Disorder Autoimmune Disease Autoimmune Diseases

Related ETFs - A few ETFs which own one or more of the above listed Central Nervous System Diseases stocks.

Symbol Grade Name Weight
PJP D PowerShares Dynamic Pharmaceuticals 2.88
PTH D Invesco DWA Healthcare Momentum ETF 2.38
FTXH D First Trust Nasdaq Pharmaceuticals ETF 2.09
FTXN B First Trust Nasdaq Oil & Gas ETF 2.09
FDM C First Trust DJ Select MicroCap ETF 1.62
View all Central Nervous System Diseases related ETFs...
Compare ETFs
  • Compare FTXH to FDM
  • Compare PJP to FTXH
  • Compare PJP to FTXN

    • Recent Signals

    Date Stock Signal Type
    2021-04-14 AVXL 50 DMA Resistance Bearish
    2021-04-14 AVXL Lower Bollinger Band Walk Weakness
    2021-04-14 AVXL Stochastic Reached Oversold Weakness
    2021-04-14 BLRX MACD Bearish Signal Line Cross Bearish
    2021-04-14 SUPN Stochastic Reached Overbought Strength
    2021-04-14 SUPN Upper Bollinger Band Walk Strength
    2021-04-14 SUPN Calm After Storm Range Contraction
    2021-04-14 SUPN New 52 Week Closing High Bullish
    2021-04-14 SUPN Doji - Bearish? Reversal
    2021-04-14 SUPN New 52 Week High Strength

    Recent News for Central Nervous System Diseases Stocks

    Date Stock Title
    Apr 13 SUPN Supernus approaches LOE for Trokendi, but Jefferies sees ‘a new product cycle’
    Apr 13 SUPN IRhythm extends losses as more downgrades pile up, Aphria cut to neutral after earnings miss; and more in today’s analyst action
    Apr 12 AVXL Anavex Life Sciences Reports the Results of Review by the Independent Data Safety Monitoring Board for its Phase 2/3 Trials of ANAVEX®2-73 in Patients with Rett Syndrome
    Apr 8 AVXL Anavex Life Sciences to Present at the 20th Annual Needham Virtual Healthcare Conference
    Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic
    Related Stock Lists: Central Nervous System Disease Treatment Of Central Nervous System Diseases Biopharmaceutical Cancers Clinical Research Clinical Trial Drug Discovery Investigational New Drug Neuroscience Pain Pharmacology Schizophrenia Acute Myeloid Leukemia Alzheimer's Alzheimer's Disease Antidepressants Attention Deficit Attention Deficit Hyperactivity Disorder Autoimmune Disease Autoimmune Diseases

    Browse All Tags